Gin Hwa Biotech Incorporation (TPEX:7806)
Taiwan · Delayed Price · Currency is TWD 62.60
-0.20 (-0.32%)
At close: Sep 24, 2026
TPEX:7806 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 535.88 | 538.65 | 435.08 | 403.56 | 139.44 | |
Revenue Growth | 5.39% | 23.80% | 7.81% | 189.41% | - |
Cost of Revenue | 392.66 | 374.88 | 296.89 | 252.5 | 89.57 |
Gross Profit | 143.22 | 163.77 | 138.19 | 151.06 | 49.87 |
Selling, General & Admin | 66.84 | 61.01 | 48.71 | 44.65 | 14.89 |
Research & Development | 11.36 | 10.79 | 5.25 | 3.43 | 1.91 |
Operating Expenses | 78.45 | 71.92 | 54.09 | 47.99 | 16.9 |
Operating Income | 64.77 | 91.85 | 84.11 | 103.07 | 32.97 |
Interest Expense | -1.82 | -2.27 | -4.86 | -2.14 | -1.09 |
Interest & Investment Income | 0.55 | 0.63 | 0.61 | 0.39 | 0.06 |
Currency Exchange Gain (Loss) | -0.1 | 0.15 | 0.01 | 0.01 | -0.08 |
Other Non Operating Income (Expenses) | 5.94 | 4.86 | 1.68 | 0.08 | - |
EBT Excluding Unusual Items | 69.34 | 95.22 | 81.55 | 101.41 | 31.87 |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | 0.17 | - | -0.36 |
Other Unusual Items | 0.03 | - | - | 1.3 | - |
Pretax Income | 69.36 | 95.21 | 81.72 | 102.71 | 31.51 |
Income Tax Expense | 13.66 | 19.87 | 14.97 | 20.33 | 1.9 |
Net Income | 55.7 | 75.33 | 66.75 | 82.38 | 29.61 |
Net Income to Common | 55.7 | 75.33 | 66.75 | 82.38 | 29.61 |
Net Income Growth | -27.05% | 12.85% | -18.97% | 178.20% | - |
Shares Outstanding (Basic) | 28 | 26 | 23 | 20 | 14 |
Shares Outstanding (Diluted) | 28 | 26 | 23 | 20 | 14 |
Shares Change | 13.45% | 11.72% | 15.33% | 48.94% | - |
EPS (Basic) | 1.99 | 2.90 | 2.90 | 4.18 | 2.19 |
EPS (Diluted) | 1.98 | 2.90 | 2.87 | 4.09 | 2.19 |
EPS Growth | -35.83% | 0.99% | -29.84% | 86.89% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -188.05 | -234.66 | -40.68 | -175.8 | 80.87 |
Free Cash Flow Per Share | -6.70 | -9.03 | -1.75 | -8.71 | 5.97 |
Dividend Per Share | 0.952 | 0.952 | 0.952 | 0.476 | 0.571 |
Dividend Growth | 0% | 0% | 100.00% | -16.66% | - |
Gross Margin | 26.73% | 30.40% | 31.76% | 37.43% | 35.77% |
Operating Margin | 12.09% | 17.05% | 19.33% | 25.54% | 23.65% |
Profit Margin | 10.39% | 13.98% | 15.34% | 20.41% | 21.23% |
Free Cash Flow Margin | -35.09% | -43.56% | -9.35% | -43.56% | 57.99% |
EBITDA | 94.22 | 119.52 | 109.44 | 118.76 | 43.87 |
EBITDA Margin | 17.58% | 22.19% | 25.16% | 29.43% | 31.46% |
D&A For EBITDA | 29.45 | 27.67 | 25.34 | 15.69 | 10.9 |
EBIT | 64.77 | 91.85 | 84.11 | 103.07 | 32.97 |
EBIT Margin | 12.09% | 17.05% | 19.33% | 25.54% | 23.65% |
Effective Tax Rate | 19.70% | 20.87% | 18.32% | 19.79% | 6.02% |
Advertising Expenses | - | 2.29 | - | - | - |